clinical trial · NCT05731947
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Colorectal CancerSolid TumorsRevumenibChemotherapy
brief summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
started
Apr 4, 2023
primary completion
Jun 30, 2025
completion
Jun 30, 2025
last updated
Jan 29, 2026
detailed description
The study will be conducted in two parts. The Phase 1 portion of the study consists of a dose escalation cohort, and a signal-seeking expansion where anti-tumor activity signals will be evaluated. The Phase 2 portion of the study will further confirm the anti-tumor activity signals of revumenib.
official title
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol